Bile acids are multifunctional modulators of the Barrett's carcinogenesis

Journal of Physiology and Pharmacology

Volumn 61, Issue 2, 2010, Pages 185-192

  Burnat, G ^a   Majka, J ^b   Konturek, P C ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Apoptosis; Barrett's carcinoma; Bile salts; Cell proliferation; Cyclooxygenase 2; DNA repair

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BILE ACID; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; DNA GLYCOSYLASE MUTY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR RELA; URSODEOXYCHOLIC ACID; CDX2 PROTEIN, HUMAN; DNA GLYCOSYLTRANSFERASE; HOMEODOMAIN PROTEIN; OXOGUANINE GLYCOSYLASE 1, HUMAN;

APOPTOSIS; ARTICLE; BARRETT ADENOCARCINOMA; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; DNA GLYCOSYLASES; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; URSODEOXYCHOLIC ACID;

EID: 77955914922     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58(Suppl 3): 141-148.
2. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2085.
3. Falk GW. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2001; 33: 109-118.
4. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005; 54(Suppl 1): 16-12.
5. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001; 96: 331-337.
6. Fein M, Fuchs KH, Stopper H, Diem S, Herderich M. Duodenogastric reflux and foregut carcinogenesis: analysis of duodenal juice in a rodent model of cancer. Carcinogenesis 2000; 21: 2079-2084.
7. Miwa K, Sahara H, Segawa M, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1996; 67: 269-274.
8. Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31: 111-118.
9. Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001; 356: 481-486.
10. Konturek PC, Kania J, Burnat G, Hahn EG. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. J Physiol Pharmacol 2006; 57(Suppl 12): 15-24.
11. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Muhldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004; 49: 1075-1083.
12. O'Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasiaadenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005; 100: 1257-1264.
13. Gerlag DM, Ransone L, Tak PP, et al. The effect of a T cellspecific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000; 165: 1652-1658.
14. Olyaee M, Sontag S, Salman W, et al. A. Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus. Gut 1995; 37: 168-173.
15. Jimenez P, Piazuelo E, Sanchez MT, Ortego J, Soteras F, Lanas A. Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. World J Gastroenterol 2005; 11: 2697-2703.
16. Nakabeppu Y, Tsuchimoto D, Furuichi M, Sakumi K. The defense mechanisms in mammalian cells against oxidative damage in nucleic acids and their involvement in the suppression of mutagenesis and cell death. Free Radic Res 2004; 38: 423-429.
17. Lewandowska U, Zelazowski M, Seta K, Byczewska M, Pluciennik E, Bednarek AK. WWOX, the tumor suppressor gene affected in multiple cancers. J Physiol Pharmacol 2009; 60(Suppl 1): 47-56.
18. Konturek PC, Kania J, Burnat G, Hahn EG, Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J Physiol Pharmacol 2005; 56(Suppl 5): 57-73.
19. Mutoh H, Hakamata Y, Sato K, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem Biophys Res Commun 2002; 294: 470-479.
20. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998; 16: 311-320.
21. Beck F, Chawengsaksophak K, Waring P, Playford RJ, Furness JB. Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. Proc Natl Acad Sci USA 1999; 96: 7318-7323.
22. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063-1068.
23. Lord RV, Brabender J, Wickramasinghe K, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005; 138: 924-931.
24. Mallo GV, Soubeyran P, Lissitzky JC, et al. Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. J Biol Chem 1998; 273: 14030-14036.
25. Phillips RW, Frierson HF Jr., Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442-1447.
26. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2006; 55: 16-25.
27. Kim S, Domon-Dell C, Wang Q, et al. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 2002; 123: 1163-1178.
28. Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 2003; 18: 392-400.
29. Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 2004; 22: 171-180.
30. Konturek SJ, Zayachkivska O, Havryluk XO, et al. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J Physiol Pharmacol 2007; 58: 361-377.
31. Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA. Role of melatonin in upper gastrointestinal tract. J Physiol Pharmacol 2007; 58(Suppl 6): 23-52.
32. Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59(Suppl 2): 33-51.
33. Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009; 60: 3-21.
34. Thor PJ, Blaut U. Helicobacter pylori infection in pathogenesis of gastroesophageal reflex disease. J Physiol Pharmacol 2006; 57(Suppl 3): 81-90.